Stimulatory and inhibitory effects of morphine on pentylenetetrazol-induced epileptic activity in rat

Samrand Rashan1, Yousef Panahi2, Emad Khalilzadeh3

  • 1Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran.

Abstract

Insights

Morphine exhibits biphasic effects on pentylenetetrazol (PTZ)-induced seizures in rats. Low doses inhibit, while higher doses exacerbate epileptiform activity, suggesting non-opioid receptor involvement.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Epileptiform activity can be experimentally induced using pentylenetetrazol (PTZ).
  • The effects of opioids, such as morphine, on seizure activity are complex and may be dose-dependent.
  • Understanding these effects is crucial for managing seizure disorders and opioid-related side effects.

Purpose of the Study:

  • To investigate the dose-dependent effects of morphine on PTZ-induced epileptiform activity in a rat model.
  • To explore the potential involvement of opioid receptors in morphine's effects on seizures.

Main Methods:

  • Adult male rats were administered varying doses of morphine (2, 5, 10 mg/kg), naloxone, or saline.
  • Epileptiform activity was induced by intraperitoneal injection of PTZ (80 mg/kg) after drug administration.
  • Electrophysiological recordings were performed in the CA1 region of the hippocampus to measure spike count and amplitude.

Main Results:

  • Morphine at 2 mg/kg decreased seizure-like events (SLEs), while 5 and 10 mg/kg increased SLEs.
  • A significant enhancement of SLEs was observed with morphine at 10 mg/kg (p < 0.01).
  • Naloxone (1 mg/kg) alone did not affect spike count but increased amplitude (p < 0.001); however, naloxone pretreatment enhanced morphine's effect on spike count (p < 0.05).

Conclusions:

  • Morphine demonstrates biphasic effects on PTZ-induced epileptiform activity, acting as an inhibitor at low doses and a potentiator at higher doses.
  • The stimulatory effects of morphine on epileptiform activity appear to be mediated through non-opioid receptors.
  • These findings highlight the complex interaction between morphine and seizure mechanisms.

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
814
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.7K